Trial Profile
Phase I trial evaluating combined radiotherapy with Panitumumab (Vectibix) in patients with muscle invasive transitional cell carcinoma of the bladder
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Oct 2018
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary)
- Indications Bladder cancer; Carcinoma
- Focus Adverse reactions
- 12 Oct 2018 Status changed from active, no longer recruiting to completed, according to the results published in the Journal of Urology
- 12 Oct 2018 Primary endpoint (Acute Toxicity rate during radiotherapy with Panitumumab treatment.) has been met, according to the results published in the Journal of Urology
- 12 Oct 2018 Results published in the Journal of Urology